Chang Yung-Yee, Liu Jia-Shou, Lai Shung-Lon, Wu Hsiu-Shan, Lan Min-Yu
Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Intern Med. 2008;47(5):467-9. doi: 10.2169/internalmedicine.47.0620. Epub 2008 Mar 3.
Nattokinase is used as a health-promoting medicine for preventing thrombosis due to its fibrinolytic activity. Cerebral microbleed is remnant of blood extravasations from the damaged vessels related to cerebral microangiopathies. We report a patient, having used aspirin for secondary stroke prevention, who had an acute cerebellar hemorrhage after taking nattokinase 400 mg daily for 7 consecutive days. In addition to the hemorrhagic lesion, multiple microbleeds were demonstrated on brain MR images. We suggest that nattokinase may increase risk of intracerebral hemorrhage in patients who have bleeding-prone cerebral microangiopathy and are receiving other antithrombotic agent at the same time.
纳豆激酶因其纤溶活性而被用作预防血栓形成的保健药物。脑微出血是与脑微血管病变相关的受损血管渗出血液的残留物。我们报告一例患者，该患者因预防二次中风服用阿司匹林，在连续7天每天服用400毫克纳豆激酶后发生急性小脑出血。除出血性病变外，脑部磁共振成像显示有多处微出血。我们认为，纳豆激酶可能会增加患有易出血性脑微血管病变且同时正在接受其他抗血栓药物治疗的患者发生脑出血的风险。
